January 12, 2022
As cited by the research report titled ‘U.S. Influenza (Flu) Vaccines Market - Growth, Demand, Trends, Opportunity, Forecasts (2021 - 2028)’, available with MarketStudyReport, United States influenza (flu) vaccines market is estimated to surpass a valuation of USD 5.5 billion over 2021-2028.
The emergence of the COVID-19 pandemic, rising awareness regarding the virus management, and introduction of quadrivalent influenza vaccines are the major factors driving United States influenza (flu) vaccines market growth. Expanding research and development activities along with increasing recommendations by governmental & advisory bodies regarding vaccination against influenza are further favoring the industry outlook.
Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/3890160/
The research literature entails an all-inclusive assessment of the past and present trends of the industry and estimation of the market size over the analysis timeframe along with information on the major restraints and challenges, as well as offers counter measures for the same.
Detailed assessment of the market segmentation and regional landscape is provided in the document with all the sub-markets being assessed comprehensively, to identify the lucrative growth avenues for stakeholders to amplify their profits.
The market report incorporates in-depth analysis of competitive outlook by focusing on the performance of the major participants in the industry. Major players profiled in the United influenza (flu) vaccines industry are Versatope Therapeutics Inc., EpiVax Inc., Imutex Ltd., FluGen Inc., Daiichi Sankyo Co. Ltd., Altimmune Inc., Pneumagen Ltd., Moderna Inc., Medicago Inc., BiondVax Pharmaceuticals Ltd., Novavax Inc., AstraZeneca plc, Seqirus, GlaxoSmithKline plc, and Sanofi Pasteur.
The competitive landscape section also entails a recent data on agreements, collaborations, partnerships, and mergers & acquisitions. The report also includes various strategies to assist stakeholders in reducing their costs, developing strategic plans, and amassing strong profits.